CD34+CD41dim Megakaryocyte Progenitors for Efficient Platelet Production
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for in vitro production of platelets are inefficient, failing to replicate the native process of producing over 1000 platelets per megakaryocyte (MK) and have not identified a distinct CD41 dim< megakaryocyte progenitor capable of efficiently maturing to the proplatelet stage.
Innovation Solution
A two-step method involving culturing hematopoietic stem cells in a serum-free medium with LDL, SCF, TPO, IL-6, and IL-9, and an AhR antagonist like StemRegenin 1 (SR1), followed by isolating a CD34 +< CD41 dim< cell population, and then culturing these cells with TPO and an AhR antagonist to produce proplatelet-bearing MKs and/or platelets.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If conventional in vitro culture methods are used to produce platelets from hematopoietic stem cells, then the process can be performed with standard culture conditions, but the production efficiency is low and fails to replicate the native process of generating over 1000 platelets per megakaryocyte
Solution Approach 1:
The invention changes culture parameters by introducing an AhR antagonist (StemRegenin 1) to the culture medium, which modifies the differentiation pathway of megakaryocytes to enhance proplatelet formation and platelet production efficiency while maintaining biological fidelity
Solution Approach 2:
The AhR antagonist acts as an intermediary substance that mediates between the culture conditions and the megakaryocyte differentiation process, enabling improved platelet production without compromising the biological authenticity of the native megakaryocyte-platelet unit formation
2Productivity
If standard culture conditions are used without AhR modulation, then the culture process is simpler, but the capacity to produce proplatelet-bearing megakaryocytes is insufficient
Solution Approach 1:
The culture method incorporates an AhR antagonist at specific concentrations during defined culture periods, changing the biochemical parameter of the culture medium to selectively enhance proplatelet-bearing megakaryocyte production without requiring complex procedural modifications
3Quantity of substance
If CD34+ cells are cultured without AhR antagonists, then the culture medium composition is simpler, but the enrichment of CD34+CD41dim megakaryocyte progenitors is insufficient
Solution Approach 1:
The addition of AhR antagonist to the culture medium changes the selective pressure parameters, enabling enrichment of the CD34+CD41dim megakaryocyte progenitor population through enhanced survival and proliferation signals specific to this cell subset
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method significantly enhances the production of proplatelet-bearing MKs and platelets, achieving up to 50 platelets per CD34 +< CD41 dim< seeded cell, with a substantially pure MK progenitor population containing at least 80% CD34 +< CD41 dim< cells.
Implementation Method 1
StemRegenin 1 (SR1), a recently developed high affinity AhR antagonist, was further reported to promote the expansion of hematopoietic progenitor cells (HPCs)
Data Source
Figure 1A~1C
Figure 2A~2C
Figure 3A~3B
AI summary
The invention relates to a method of producing CD34+CD4dim megakaryocyte (MK) progenitor cells, and substantially pure cell population of megakaryocyte precursor cells obtained by said method. The invention also relates to a method of producing proplatelet- bearing MKs and/or platelets using the CD34+CD4dimcells.